The Third Wave of Biotechnology –Industrial- Investor Briefing Scheduled
Washington, D.C. (January 8, 2003) – The Biotechnology Industry Organization (BIO) will address the market potential for industrial biotechnology during an analyst and investor briefing, The Third Wave of Biotechnology, on January 23 in New York City at the New York Academy of Sciences. Attendance at this event is by invitation only. Analysts and investors interested in attending should contact Lauren Pannenbacker at (202) 962-6641, or via email at firstname.lastname@example.org for registration approval. Credentialed press should contact Carrie Housman of BIO at (202) 962 9234, or via email at email@example.com.
This half-day educational event will focus solely on industrial biotechnology and emphasize the progress this sector has made in the industrial enzyme, bioenergy and bio-based materials markets, which are rapidly transforming multiple products and industries. The event will begin with a luncheon keynote address on the market opportunities for industrial biotech by Rolff Bachmann, principle of McKinsey & Co.
The luncheon address will be followed by four moderator-lead panel sessions: Driving a $100 Billion Market, Perspectives on the Industry; Industrial Biotechnology Supporting the Needs of an Advancing Society; Biotechnology. It’s Not Just Health care; and Technology Drivers of the Industry.
Confirmed panel participants include: Roger Wyse, managing director of Burrill & Company; Patrick Gruber, vice president and chief technology officer of Cargill-Dow LLP; Alan Shaw, president and chief executive officer of Codexis; Laura Berezin, partner of Cooley Godward; Ari Patrinos, associate director of science for Biological and Environmental Research of the Department of Energy; Tom Lane of Dow Corning; Phillip van Lelyveld, manager public affairs Life Science Products of DSM Group; John Ranieri, vice president for Bio-based Materials of DuPont; Jean Jacques Bienaimé, chief executive officer of Genencor International; Jeff Zekauskas, analyst of JP Morgan; James Barber, chief executive officer of Metabolix; Per Falholt, executive vice president and chief scientific officer of NovoZymes; Jonathan Dordick, chair of the Department of Chemical Engineering of Rensselaer Polytechnic Institute; Steven Goldby, chief executive officer of Symyx Corporation.
“We are very pleased that The Third Wave of Biotechnology has attracted the support of prominent industry business leaders,” said Brent Erickson, vice president, Industrial and Environmental Section of BIO. “The event’s plenary panel format combines the insights of industry thought leaders and practitioners to provide a truly unique perspective on the industrial side of biotechnology – the fastest growing and newest sector of biotechnology. This briefing should be of great interest to analysts and investors who cover the biotechnology space, but also to those who cover the chemical and energy industries.”
The Third Wave of Biotechnology is being sponsored in part by Nasdaq, Cooley Godward, Burrill & Company, DSM NV, Cargill Dow and Genencor International.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information on BIO, please visit www.bio.org.
# # #